Compare Cronos Group Inc (CRON) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Boston Beer Company Inc — how do they compare? Cronos Group Inc trades at $3.08 (market cap $1.11B), while Boston Beer Company Inc trades at $179.73 (market cap $1.86B). The key difference: Boston Beer Company Inc is the larger of the two by market cap, and Cronos Group Inc is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals.
| CRON | SAM | |
|---|---|---|
Market Cap | $1.11B | $1.86B |
Sector | Health | Consumer Staples |
52-Week High | $3.27 | $260.05 |
52-Week Low | $2.30 | $161.08 |
Enterprise Value | $310.67M | $1.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.10 with a 0.98% daily gain, showing bullish technical momentum. The company delivered strong Q2 2026 results with 58% YoY revenue growth and earnings beat, while maintaining #1 market share in Canadian vapes and edibles. Despite negative net income in 2025, revenue growth accelerated to $147M with improving margins. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near $3 resistance.
Outlook remains positive with international expansion and European cannabis legalization driving growth, though competitive pressures and execution risks persist. Analyst consensus is mixed with 60% hold ratings, reflecting cautious optimism about CRON's turnaround trajectory from previous losses to projected 39% profit margin by 2026.
The Boston Beer Company (SAM) trades at $186.61, up 1.94% on the day, with a bullish technical signal driven by moving averages. The stock shows mixed fundamentals; while the P/E ratio of 22.66 and P/S of 0.99 suggest reasonable valuation, recent quarterly earnings have missed expectations, and the company faces volume declines in core brands. Positive cash flow and innovation in ready-to-drink products provide some offset. Analyst sentiment is cautious, with a consensus price target of $207.33 but a majority hold rating.
Outlook: Upside exists if new product growth accelerates and margins improve, but risks from weak demand and competitive pressure persist. The stock's trajectory hinges on reversing volume trends and achieving future earnings targets, making it a hold for now with watchful optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
